
Annovis Bio (ANVS) Stock Forecast & Price Target
Annovis Bio (ANVS) Analyst Ratings
Bulls say
Annovis Bio is a promising clinical stage drug platform company with a positive outlook as its flagship candidate, buntanetap, has achieved statistical significance in early trials for Alzheimer's and other neurodegenerative diseases. With a strong FDA accepted trial protocol and enrollment completion for its phase 2 and 3 trials, the company has a potentially lucrative market ahead. Risks to the positive outlook include financing and pipeline risks, potential trial failures, and competition in the difficult-to-treat neurodegenerative market.
Bears say
Annovis Bio is currently collaborating on buntanetap, its flagship candidate currently in clinical trials for various neurodegenerative diseases, and has a 12-month DCF-based price target of $17. Despite potential launch in 2028E for early AD and a 25% probability of approval, it has not accounted for ex-US sales/royalties or other pipeline programs, and the 15% discount rate is reflective of a clinical-stage company's WACC.
This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.
Annovis Bio (ANVS) Analyst Forecast & Price Prediction
Start investing in Annovis Bio (ANVS)
Order type
Buy in
Order amount
Est. shares
0 shares